UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality

Journal of the American College of Cardiology, 2018-02, Vol.71 (7), p.752-763

2018

Volltextzugriff (PDF)

Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2008-10, Vol.178 (7), p.729-737

2008

Volltextzugriff (PDF)

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Respiratory research, 2021-02, Vol.22 (1), p.34-9, Article 34

2021

Volltextzugriff (PDF)

Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset

Cardiology and therapy, 2024-06, Vol.13 (2), p.315-339

2024

Volltextzugriff (PDF)

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

Pulmonary therapy, 2024-03, Vol.10 (1), p.85-107

2024

Volltextzugriff (PDF)

Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study

Pulmonary circulation, 2020-10, Vol.10 (4), p.1-4

2020

Volltextzugriff (PDF)

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension

ERJ open research, 2023-01, Vol.9 (1), p.456-2022

2023

Volltextzugriff (PDF)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy

Pulmonary circulation, 2023-04, Vol.13 (2), p.e12226-n/a

2023

Volltextzugriff (PDF)

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

Pulmonary circulation, 2022-10, Vol.12 (4), p.e12150-n/a

2022

Volltextzugriff (PDF)

Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting

Pulmonary circulation, 2020-04, Vol.10 (2), p.1-9

2020

Volltextzugriff (PDF)

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2024-01, Vol.83 (4), p.473-484

2024

Volltextzugriff (PDF)

Lessons from the COMPASS-3 Study

Pulmonary circulation, 2018-01, Vol.8 (1), p.1-3

2018

Volltextzugriff (PDF)

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study

Circulation (New York, N.Y.), 2019-05, Vol.139 (21), p.2440-2450

2019

Volltextzugriff (PDF)

MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study

The European respiratory journal, 2024-09, Vol.64 (5), p.2401110

2024

Volltextzugriff (PDF)

Treatment algorithm for pulmonary arterial hypertension

The European respiratory journal, 2024-10, Vol.64 (4), p.2401325

2024

Volltextzugriff (PDF)

Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids

Chest, 2018-09, Vol.154 (3), p.532-540

2018

Volltextzugriff (PDF)

Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study

Chest, 2021-07, Vol.160 (1), p.277-286

2021

Volltextzugriff (PDF)

Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study

The Journal of heart and lung transplantation, 2024-08, Vol.43 (12), p.1998-2007

2024

Volltextzugriff (PDF)

Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)

The Journal of heart and lung transplantation, 2024-02, Vol.43 (2), p.272-283

2024

Volltextzugriff (PDF)

Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities

European journal of heart failure, 2024-07

2024

Volltextzugriff (PDF)

Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial

Chest, 2018-10, Vol.154 (4), p.848-861

2018

Volltextzugriff (PDF)

Right Heart Adaptation to Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2013-12, Vol.62 (25), p.D22-D33

2013

Volltextzugriff (PDF)

Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction

Journal of thoracic disease, 2021-03, Vol.13 (3), p.1466-1475

2021

Volltextzugriff (PDF)

The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study

JMIR research protocols, 2021-05, Vol.10 (5), p.e25397-e25397

2021

Volltextzugriff (PDF)

Reply

Journal of the American College of Cardiology, 2022-02, Vol.79 (7), p.e177

2022

Volltextzugriff (PDF)

1 – 25 von 168

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(147)
Mit Volltextzugriff
(140)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality

Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension

Lessons from the COMPASS-3 Study

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study

MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study

Treatment algorithm for pulmonary arterial hypertension

Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids

Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study

Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study

Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)

Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities

Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial

Right Heart Adaptation to Pulmonary Arterial Hypertension

Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction

The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study

Reply

Aktive Filter

Suchergebnisse filtern